PSO

WiMi Announced the Optimization of Artificial Neural Networks Using Group Intelligence Algorithm

Retrieved on: 
Wednesday, December 20, 2023
Cloud, Neuron, Movement, Data, AFSA, WIMI, Augmented reality, Animal, Holography, ACO, Bias, PSO, Intelligence, Algorithm, Environment

Beijing, Dec. 20, 2023 (GLOBE NEWSWIRE) -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it adopted a group intelligence algorithm to optimize the artificial neural network.

Key Points: 
  • Beijing, Dec. 20, 2023 (GLOBE NEWSWIRE) -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it adopted a group intelligence algorithm to optimize the artificial neural network.
  • The group intelligence algorithm is a meta-heuristic optimization algorithm inspired by observing the behavioral patterns of groups of animals and insects as their environment change.
  • This allows group intelligence algorithms to solve complex optimization problems using the interaction between groups of artificial search agents and the environment.
  • WiMi used a group intelligence algorithm to optimize artificial neural networks to improve the generalization ability of artificial neural networks by optimizing the connection weights, weights, and biases or network structure.

Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA® (tapinarof) Cream, 1% for the Treatment of Plaque Psoriasis in the Head and Neck Region in Adults

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, JD, PGA, Neck, Itch, Safety, Head, Scalp, Ageing, Incidence, Headache, Sinusitis, Face, Irritation, Folliculitis, Nose, Common, Rash, Psoriasis, Stinger, Patient, Week, Global Assessment of Functioning, Body surface area, FDA, Prescription, Therapy, PSQ, LTS, Success, Pain, Swelling, PSO, Quality of life, FAAD, Pharmaceutical industry, Silviculture, Cosmetics, Birth control, MD, PASI

“Up to 80% of patients with plaque psoriasis experience scalp psoriasis, making it one of the most affected areas of the body.

Key Points: 
  • “Up to 80% of patients with plaque psoriasis experience scalp psoriasis, making it one of the most affected areas of the body.
  • DMVT-505-4002 (NCT05789576) was a Phase 4, open-label multi-center study to investigate the efficacy and safety of VTAMA (tapinarof) cream, 1% for the treatment of adults with plaque psoriasis specifically in the head and neck region.
  • The trial enrolled 31 participants with mild, moderate, and severe head and neck plaque psoriasis (tPGA score ≥2) aged 18 years or older at 8 sites across the U.S.
  • Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

Community Health Systems’ Decade Long Commitment to Patient Safety Featured in NEJM Catalyst

Retrieved on: 
Wednesday, November 15, 2023
Other Health, Hospitals, Health, Nursing, Managed Care, Patient safety, CHS, Safety, NYSE, Patient safety organization, Community Health Systems, AHRQ, Risk, Patient, Data analysis, Caregiver, CYH, Hospital, Approximation error, PSO, Face, Fungal infection, Medical device, Medicine

Since then, the hospitals have achieved and maintained an 89% reduction in their Serious Safety Event Rate.

Key Points: 
  • Since then, the hospitals have achieved and maintained an 89% reduction in their Serious Safety Event Rate.
  • Through the PSO, CHS established a safety base-line in 2012 and began its journey to zero preventable harm.
  • “The catalyst in our journey to zero preventable harm was in analyzing baseline data for serious safety events and recognizing that preventable patient harm was occurring, similar to other health systems and consistent with reported trends,” says Lynn Simon, M.D., President, Healthcare Innovation and Chief Medical Officer of Community Health Systems.
  • “Across CHS, safety is a core value embedded in the hearts and minds of our caregivers – a commitment that is constant, unchanging, and unyielding in the face of the latest trends or competing priorities.”

Early Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

Retrieved on: 
Thursday, November 2, 2023
Research, Medical Devices, Medical Supplies, Genetics, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, FAAD, Psoriasis, AD, Mycosis fungoides, Skin, Castle, PSO, MF, Atopic dermatitis, Patient, Gene expression, Diagnosis, Medical device, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing the ability of its pipeline test in development to distinguish between responders and non-responders to an atopic dermatitis (AD) therapy and also distinguish between AD, psoriasis (PSO) and mycosis fungoides (MF) skin lesions.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing the ability of its pipeline test in development to distinguish between responders and non-responders to an atopic dermatitis (AD) therapy and also distinguish between AD, psoriasis (PSO) and mycosis fungoides (MF) skin lesions.
  • The goal of Castle’s innovative pipeline initiative is to develop a genomic test aimed at guiding systemic therapy selection for patients with moderate-to-severe AD, PSO and related conditions.
  • Additional updates regarding development of this pipeline program are expected in 2024.
  • Additional updates regarding development of this pipeline program are expected in 2024.

AdventHealth Hospitals Win National Safety Award for Reducing Patient Falls

Retrieved on: 
Thursday, November 2, 2023
Agency for Healthcare Research and Quality, Thought, AdventHealth, Agency, Safety, 28th Combat Support Hospital (United States), Learning, PSO, Boot, Risk management, Risk assessment, Hospital, Annual general meeting, Culture, Quality, Patient, Patient safety, Death, ECRI, Nursing, MD

PLYMOUTH MEETING, Pa., Nov. 2, 2023 /PRNewswire/ -- ECRI, the nation's largest independent nonprofit patient safety organization (PSO), names AdventHealth Zephyrhills and AdventHealth Dade City hospitals in Pasco County, FL, winners of the 2023 Safety Excellence Award.

Key Points: 
  • ECRI and the Institute for Safe Medication Practices PSO names AdventHealth Zephyrhills and AdventHealth Dade City hospitals winners of the 2023 Safety Excellence Award.
  • PLYMOUTH MEETING, Pa., Nov. 2, 2023 /PRNewswire/ -- ECRI, the nation's largest independent nonprofit patient safety organization (PSO), names AdventHealth Zephyrhills and AdventHealth Dade City hospitals in Pasco County, FL, winners of the 2023 Safety Excellence Award.
  • The annual Safety Excellence Award recognizes outstanding patient safety initiatives led by PSOs that partner with ECRI, and members of ECRI and the ISMP PSO.
  • The AdventHealth Patient Falls Bootcamp helped frontline hospital staff identify safety hazards, recognize the characteristics of a high-risk patient, and ensure fall risk strategies were in place.

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Finance, Oncology, Health, FDA, Professional Services, Clinical Trials, Congress, Bristol Myers Squibb, NYSE, PASI, Coronary thrombosis, Journal of the European Academy of Dermatology and Venereology, Abstract, Research, Circulatory system, Aes, AE, Risk, Bolivian National Congress, 1985–1989, Malignancy, Death, University, Week, MPH, Safety, Psoriasis, Conditional sentence, Psoriasis Area and Severity Index, Shingles, Plaque, CPU socket, Head, PSO, LTE, BMY, Patient, Pharmaceutical industry, Dermatology, MD, Venereology, Immunology, Deucravacitinib, TYK2

Bristol Myers Squibb (NYSE:BMY) today announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) today announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.
  • Sotyktu demonstrated a consistent safety profile with no increases in the rates of adverse events (AEs) or serious AEs over time, and no emergence of any new safety signals.
  • The efficacy analysis assessed 513 patients who received continuous Sotyktu treatment from Day 1 in the pivotal POETYK PSO-1 and POETYK PSO-2 trials and transitioned to the LTE trial.
  • “These new data validate the potential of Sotyktu to provide long-term, clinically relevant improvement for individuals living with moderate-to-severe plaque psoriasis.”
    Bristol Myers Squibb thanks the patients and investigators involved in the POETYK PSO clinical trial program.

Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress

Retrieved on: 
Monday, October 9, 2023
Congress, Red, Quality of life, PASI, European Academy of Allergy and Clinical Immunology, Treatment, Oral, Abstract, SPRING, Janssen, Health and Quality of Life Outcomes, Johnson & Johnson, Janssen Pharmaceuticals, Disease, Real Life, HOUSE, Psoriasis Area and Severity Index, Journal of the European Academy of Dermatology and Venereology, Macrophage, Plaque, Overalls, Safety, Science, Political moderate, Pharmaceutical industry, Medical imaging, Vaccine, Psoriasis, Dermatology, Venereology, Libido, PSO, Patient

SPRING HOUSE, Pa., Oct. 9, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced that 30 company-sponsored presentations will be featured at the European Academy of Dermatology and Venereology (EADV) Congress taking place in Berlin, Germany from October 11-14, 2023. Janssen will present new data on the underlying science of the treatment of psoriasis (PsO), including results from the Phase 3b GUIDE trial highlighting early intervention with TREMFYA® (guselkumab) (Abstract #FC08.5)1 and systemic pharmacodynamica response data for JNJ-2113 from the Phase 2 FRONTIER 1 trial (Abstract #FC08.2).2

Key Points: 
  • "Patients are waiting for a new option with the goal of helping manage their plaque psoriasis symptoms, which could potentially transform the treatment paradigm.
  • The data from these presentations add to the comprehensive body of scientific evidence for our investigational and established therapies, potentially offering people living with moderate to severe plaque psoriasis much-needed relief from their symptoms."
  • A selection of Janssen-sponsored abstracts being featured at EADV is provided below.
  • Systemic pharmacodynamics is the study of the biochemical and physiologic effects of drugs in the body.

X-Rite Showcases How Digital Workflow Solutions Keep Colors Connected at PRINTING United

Retrieved on: 
Tuesday, October 3, 2023
Pantone, Maintenance, Hong Kong International Printing and Packaging Fair, Wi-Fi, Workflow, ISO, ICC, PSO, Quality control, Paper, Ecosystem, Commercial, Textile, 3D printing

GRAND RAPIDS, Mich., Oct. 3, 2023 /PRNewswire-PRWeb/ -- At PRINTING United, October 18-20 in Atlanta, GA, X-Rite Incorporated and Pantone LLC, will demonstrate how a connected ecosystem of color measurement, specification, formulation, and quality control solutions helps printers simplify print workflows, exceed brand requirements, and improve print quality. Commercial, packaging, and specialty printers can reduce waste, boost profitability, and grow their print business by keeping their color data digitally connected from design through production.

Key Points: 
  • At PRINTING United, X-Rite will demonstrate its connected ecosystem of color measurement, specification, formulation, and quality control solutions to help printers reduce production costs, minimize wasted inks and substrates, and maximize profitability.
  • Commercial, packaging, and specialty printers can reduce waste, boost profitability, and grow their print business by keeping their color data digitally connected from design through production.
  • With a digital color workflow, print providers get to approved color faster, saving time, improving productivity while reducing ink and material waste."
  • Visitors at PRINTING United Expo can explore X-Rite's comprehensive range of color workflow solutions at booth C1713, including:
    eXact 2 ™ Portable Spectrophotometer: X-Rite's most versatile, connected, and easy-to-use measurement device for optimizing the print workflow, from formulation through quality control.

IFS to acquire Falkonry AI

Retrieved on: 
Thursday, August 31, 2023
Cloud, IDC, Maintenance, FSM, United States Navy, MES, Defense, Harbour Energy, Improper integral, Artificial intelligence in industry, Mobile enterprise asset management, ESM, Intelligence, ERP, ICEX: US Navy Mission in Arctic, Organization, PSO, Acquisition, SSAB, Enterprise resource planning, Anomaly, Air force, Artificial intelligence, AI, Field service management, Automation, Asset management, Customer service, EAM

CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ -- IFS, the global cloud enterprise software company, today announced it has signed a definitive agreement to acquire Falkonry, Inc. a California-based Industrial AI software company that provides automated, high-speed data analysis to the manufacturing and defense industries. The AI-based, self-learning solution continuously monitors large volumes of data for assets, machines, systems, and industrial processes to discover and analyze unusual behavior and causes of failures.

Key Points: 
  • CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ -- IFS, the global cloud enterprise software company, today announced it has signed a definitive agreement to acquire Falkonry, Inc. a California-based Industrial AI software company that provides automated, high-speed data analysis to the manufacturing and defense industries.
  • IFS CEO, Darren Roos, commented: "Falkonry is unique in the market because its technology is agnostic and also it does not require data scientists.
  • The combination of Falkonry and Poka with IFS Cloud makes IFS the most compelling vendor for organizations wanting to establish the most progressive and effective Smart Factories of the future.
  • IFS expects the acquisition of Falkonry to complete in Q4 2023.

IFS to acquire Falkonry AI

Retrieved on: 
Thursday, August 31, 2023
Cloud, IDC, Maintenance, FSM, United States Navy, MES, Defense, Harbour Energy, Improper integral, Artificial intelligence in industry, Mobile enterprise asset management, ESM, Intelligence, ERP, ICEX: US Navy Mission in Arctic, Organization, PSO, Acquisition, SSAB, Enterprise resource planning, Anomaly, Air force, Artificial intelligence, AI, Field service management, Automation, Asset management, Customer service, EAM

CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ -- IFS, the global cloud enterprise software company, today announced it has signed a definitive agreement to acquire Falkonry, Inc. a California-based Industrial AI software company that provides automated, high-speed data analysis to the manufacturing and defense industries. The AI-based, self-learning solution continuously monitors large volumes of data for assets, machines, systems, and industrial processes to discover and analyze unusual behavior and causes of failures.

Key Points: 
  • CUPERTINO, Calif., Aug. 31, 2023 /PRNewswire/ -- IFS, the global cloud enterprise software company, today announced it has signed a definitive agreement to acquire Falkonry, Inc. a California-based Industrial AI software company that provides automated, high-speed data analysis to the manufacturing and defense industries.
  • IFS CEO, Darren Roos, commented: "Falkonry is unique in the market because its technology is agnostic and also it does not require data scientists.
  • The combination of Falkonry and Poka with IFS Cloud makes IFS the most compelling vendor for organizations wanting to establish the most progressive and effective Smart Factories of the future.
  • IFS expects the acquisition of Falkonry to complete in Q4 2023.